Join our daily newsletter At The Bell to receive exclusive market insights
- A new clinical service has been launched at more than 100 pharmacies in the United Kingdom that includes Lumos Diagnostics’ (LDX) rapid FebriDx point-of-care test
- The NHS Liverpool Clinical Commissioning Group and Community Pharmacy Liverpool will offer Lumos’ 10-minute FebriDx tests
- FebriDx will be used to for patients with an acute cough at pharmacies to enable rapid diagnoses and appropriate antibiotic prescribing
- The company says using FebriDx helps healthcare providers rule out bacterial infections which can help reduce unnecessary use of antibiotics
- LDX shares end the trading day steady at 99.5 cents
A new clinical service has been launched at more than 100 pharmacies in the United Kingdom that includes Lumos Diagnostics’ (LDX) rapid FebriDx point-of-care test.
The NHS Liverpool Clinical Commissioning Group and Community Pharmacy Liverpool will offer Lumos’ 10-minute FebriDx tests.
Lumos said the FebriDx test will be used for patients suffering an acute cough who present at pharmacies across Liverpool under a new minor ailments service called Pharmacy First.
The test enables rapid diagnoses and appropriate antibiotic prescribing without the need for a general practitioner appointment first, according to the company.
Lumos said clinical studies show the FebriDx test allows healthcare providers to rule out bacterial infections for their patients with 99 per cent confidence, helping reduce the unnecessary use of antibiotics and reduce antimicrobial resistance.
FebriDx is approved for use by qualified healthcare professionals in the UK, Europe, Canada, Australia and UAE.
The company said an application for US regulatory clearance of FebriDx is currently under review by the FDA and on track for a decision in the 2022 FY.
LDX shares ended the trading day steady at 99.5 cents.
